Cancer Research Meeting Calendar Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, L. L.
Right arrow Articles by Frazier, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, L. L.
Right arrow Articles by Frazier, M. L.
[Cancer Research 64, 5913-5919, September 1, 2004]
© 2004 American Association for Cancer Research

Advances in Brief

A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors

Lei L. Chen1, Jonathan C. Trent1, Elsie F. Wu2, Gregory N. Fuller3, Latha Ramdas3, Wei Zhang3, Austin K. Raymond3, Victor G. Prieto3, Caroline O. Oyedeji1, Kelly K. Hunt4, Raphael E. Pollock4, Barry W. Feig4, Kimberly J. Hayes5, Haesun Choi6, Homer A. Macapinlac7, Walter Hittelman8, Marco A. Velasco9, Shreyaskumar Patel1, Michael A. Burgess1, Robert S. Benjamin1 and Marsha L. Frazier2

Departments of 1 Sarcoma, 2 Epidemiology, 3 Pathology, 4 Surgery, 5 Cytogenetics, 6 Diagnostic Radiology, and 7 Nuclear Medicine, 8 Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and 9 Vel-Lab Research, Houston, Texas

KIT gain of function mutations play an important role in the pathogenesis of gastrointestinal stromal tumors (GISTs). Imatinib is a selective tyrosine kinase inhibitor of ABL, platelet-derived growth factor receptor (PDGFR), and KIT and represents a new paradigm of targeted therapy against GISTs. Here we report for the first time that, after imatinib treatment, an additional specific and novel KIT mutation occurs in GISTs as they develop resistance to the drug. We studied 12 GIST patients with initial near-complete response to imatinib. Seven harbored mutations in KIT exon 11, and 5 harbored mutations in exon 9. Within 31 months, six imatinib-resistant rapidly progressive peritoneal implants (metastatic foci) developed in five patients. Quiescent residual GISTs persisted in seven patients. All six rapidly progressive imatinib-resistant implants from five patients show an identical novel KIT missense mutation, 1982T->C, that resulted in Val654Ala in KIT tyrosine kinase domain 1. This novel mutation has never been reported before, is not present in pre-imatinib or post-imatinib residual quiescent GISTs, and is strongly correlated with imatinib resistance. Allelic-specific sequencing data show that this new mutation occurs in the allele that harbors original activation mutation of KIT.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
G. D. Demetri, M. C. Heinrich, J. A. Fletcher, C. D.M. Fletcher, A. D. Van den Abbeele, C. L. Corless, C. R. Antonescu, S. George, J. A. Morgan, M. H. Chen, et al.
Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
Clin. Cancer Res., September 15, 2009; 15(18): 5902 - 5909.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Negri, G. M. Pavan, E. Virdis, A. Greco, M. Fermeglia, M. Sandri, S. Pricl, M. A. Pierotti, S. Pilotti, and E. Tamborini
T670X KIT Mutations in Gastrointestinal Stromal Tumors: Making Sense of Missense
J Natl Cancer Inst, February 4, 2009; 101(3): 194 - 204.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Heinrich, R. G. Maki, C. L. Corless, C. R. Antonescu, A. Harlow, D. Griffith, A. Town, A. Mckinley, W.-B. Ou, J. A. Fletcher, et al.
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
J. Clin. Oncol., November 20, 2008; 26(33): 5352 - 5359.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Yamaguchi, R. Nakayama, K. Honda, H. Ichikawa, T. Hasegawa, M. Shitashige, M. Ono, A. Shoji, T. Sakuma, H. Kuwabara, et al.
Distinct Gene Expression-Defined Classes of Gastrointestinal Stromal Tumor
J. Clin. Oncol., September 1, 2008; 26(25): 4100 - 4108.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. F. Bellon, P. Kaplan-Lefko, Y. Yang, Y. Zhang, J. Moriguchi, K. Rex, C. W. Johnson, P. E. Rose, A. M. Long, A. B. O'Connor, et al.
c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations
J. Biol. Chem., February 1, 2008; 283(5): 2675 - 2683.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
C M Gentile, A A Lombardi, and J O Croxatto
Choroidal metastasis from gastrointestinal stromal tumour: a case report
Br J Ophthalmol, January 1, 2008; 92(1): 156 - 157.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Desai, S. Shankar, M. C. Heinrich, J. A. Fletcher, C. D. Fletcher, J. Manola, J. A. Morgan, C. L. Corless, S. George, K. Tuncali, et al.
Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors
Clin. Cancer Res., September 15, 2007; 13(18): 5398 - 5405.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. B. Gendreau, R. Ventura, P. Keast, A. D. Laird, F. M. Yakes, W. Zhang, F. Bentzien, B. Cancilla, J. Lutman, F. Chu, et al.
Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647
Clin. Cancer Res., June 15, 2007; 13(12): 3713 - 3723.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F.=C> Miselli, P. Casieri, T. Negri, M. Orsenigo, M. S. Lagonigro, A. Gronchi, M. Fiore, P. G. Casali, R. Bertulli, A. Carbone, et al.
c-Kit/PDGFRA Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors
Clin. Cancer Res., April 15, 2007; 13(8): 2369 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. R. Jamali, S. S. Darwiche, N. El-Kinge, A. Tawil, and A. M. Soweid
Disease Progression Following Imatinib Failure in Gastrointestinal Stromal Tumors: Role of Surgical Therapy
Oncologist, April 1, 2007; 12(4): 438 - 442.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. G. Roberts, A. F. Odell, E. M. Byrnes, R. M. Baleato, R. Griffith, A. B. Lyons, and L. K. Ashman
Resistance to c-KIT kinase inhibitors conferred by V654A mutation
Mol. Cancer Ther., March 1, 2007; 6(3): 1159 - 1166.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Heinrich, C. L. Corless, C. D. Blanke, G. D. Demetri, H. Joensuu, P. J. Roberts, B. L. Eisenberg, M. von Mehren, C. D.M. Fletcher, K. Sandau, et al.
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
J. Clin. Oncol., October 10, 2006; 24(29): 4764 - 4774.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Kosaka, Y. Yatabe, H. Endoh, K. Yoshida, T. Hida, M. Tsuboi, H. Tada, H. Kuwano, and T. Mitsudomi
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Clin. Cancer Res., October 1, 2006; 12(19): 5764 - 5769.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. von Bubnoff, P. W. Manley, J. Mestan, J. Sanger, C. Peschel, and J. Duyster
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
Blood, August 15, 2006; 108(4): 1328 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
L Tornillo and L M Terracciano
An update on molecular genetics of gastrointestinal stromal tumours.
J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Prenen, J. Cools, N. Mentens, C. Folens, R. Sciot, P. Schoffski, A. Van Oosterom, P. Marynen, and M. Debiec-Rychter
Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate
Clin. Cancer Res., April 15, 2006; 12(8): 2622 - 2627.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Wardelmann, S. Merkelbach-Bruse, K. Pauls, N. Thomas, H.-U. Schildhaus, T. Heinicke, N. Speidel, T. Pietsch, R. Buettner, D. Pink, et al.
Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate.
Clin. Cancer Res., March 15, 2006; 12(6): 1743 - 1749.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
X. Hong, H. Choi, E. M. Loyer, R. S. Benjamin, J. C. Trent, and C. Charnsangavej
Gastrointestinal Stromal Tumor: Role of CT in Diagnosis and in Response Evaluation and Surveillance after Treatment with Imatinib.
RadioGraphics, March 1, 2006; 26(2): 481 - 495.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M.-H. Ryu, J.-L. Lee, H. M. Chang, T. W. Kim, H. J. Kang, H. J. Sohn, J. S. Lee, and Y.-K. Kang
Patterns of Progression in Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate
Jpn. J. Clin. Oncol., January 1, 2006; 36(1): 17 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. R. McLean, M. Gana-Weisz, B. Hartzoulakis, R. Frow, J. Whelan, D. Selwood, and C. Boshoff
Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala
Mol. Cancer Ther., December 1, 2005; 4(12): 2008 - 2015.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. A. Carter, L. M. Wodicka, N. P. Shah, A. M. Velasco, M. A. Fabian, D. K. Treiber, Z. V. Milanov, C. E. Atteridge, W. H. Biggs III, P. T. Edeen, et al.
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
PNAS, August 2, 2005; 102(31): 11011 - 11016.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. P. Rubin, C. R. Antonescu, J. P. Scott-Browne, M. L. Comstock, Y. Gu, M. R. Tanas, C. B. Ware, and J. Woodell
A Knock-In Mouse Model of Gastrointestinal Stromal Tumor Harboring Kit K641E
Cancer Res., August 1, 2005; 65(15): 6631 - 6639.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. S. Krause and R. A. Van Etten
Tyrosine Kinases as Targets for Cancer Therapy
N. Engl. J. Med., July 14, 2005; 353(2): 172 - 187.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. R. Antonescu, P. Besmer, T. Guo, K. Arkun, G. Hom, B. Koryotowski, M. A. Leversha, P. D. Jeffrey, D. Desantis, S. Singer, et al.
Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation
Clin. Cancer Res., June 1, 2005; 11(11): 4182 - 4190.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. L. Kwak, R. Sordella, D. W. Bell, N. Godin-Heymann, R. A. Okimoto, B. W. Brannigan, P. L. Harris, D. R. Driscoll, P. Fidias, T. J. Lynch, et al.
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
PNAS, May 24, 2005; 102(21): 7665 - 7670.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
R. Chen and W. Plunkett
Sequential Blockade of Oncogenic Kinases
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 344 - 348.
[Full Text] [PDF]

Home page
 NEJMHome page
S. Kobayashi, T. J. Boggon, T. Dayaram, P. A. Janne, O. Kocher, M. Meyerson, B. E. Johnson, M. J. Eck, D. G. Tenen, and B. Halmos
EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib
N. Engl. J. Med., February 24, 2005; 352(8): 786 - 792.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. von Bubnoff, D. R. Veach, H. van der Kuip, W. E. Aulitzky, J. Sanger, P. Seipel, W. G. Bornmann, C. Peschel, B. Clarkson, and J. Duyster
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor
Blood, February 15, 2005; 105(4): 1652 - 1659.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.